Modification of platelet adhesion by antiplatelet drugs helps prevent cardiovascular complications of diabetes mellitus.
If it could be shown that: The abnormal platelet function in diabetes contributes to the development of cardiovascular complications of diabetes, the abnormal platelet function is a consequence of the diabetic state, the level of blood sugar control or insulin administration, antiplatelet drugs improve the abnormal platelet function independent of the diabetic state and its treatment, the altered platelet function induced by antiplatelet drugs diminishes the evolution of cardiovascular complications, the addition of antiplatelet drugs to the management of diabetes may be reasonable. Specifically designed animal experiments are necessary to provide the scientific basis for designing appropriate clinical trials.
D000818:Animals; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000097:blood*; D003921:Diabetes Mellitus, Experimental / Q000097:blood; D006801:Humans; D010973:Platelet Adhesiveness / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*
D010975:Platelet Aggregation Inhibitors